Clinical Trials Logo

Clinical Trial Summary

Background

Focal dystonia is a brain disorder. It affects a muscle or muscles in a specific part of the body. Researchers think it may be related to excessive training or practice. They want to know more about how much training might trigger focal dystonia.

Objectives:

To study why people develop focal dystonia. To study how brain plasticity changes with focal dystonia.

Eligibility:

People at least 18 years of age with focal dystonia.

Healthy volunteers the same age are also needed.

Design:

Participants will be screened with a physical exam and questions. They may have blood and urine tests.

Participants will have up to 3 testing visits.

Participants will have small electrodes stuck on the skin on the hands or arms. Muscle activity will be recorded.

Participants will have transcranial magnetic stimulation (TMS). A wire coil will be placed onto the scalp. A brief electrical current will pass through the coil. The current will create a magnetic field that affects brain activity.

Participants may be asked to tense certain muscles or do simple actions during TMS.

A nerve at the wrist will get weak electrical stimulation. The stimulation may be paired with TMS for very short times.

Participants will receive repeated magnetic pulses. Participants will receive a total of 150 pulses during a 10-second period. An entire testing visit will last about 3 hours.

...


Clinical Trial Description

Objectives

Simulation paradigms can induce plastic changes in brain excitability. Paired associative stimulation (PAS) with an interstimulus interval of 25 ms (PAS25) induces a long-term potentiation (LTP)-like effect while that at an interval of 10 ms (PAS10) induces a long-term depression (LTD)-like effect. The LTP-like effect induced by PAS25 is exaggerated in patients with focal dystonia. The LTD-like effect with PAS10 is also increased in focal dystonia but not in the target area of PAS. Depotentiation refers to the reversal of LTP by which LTP is abolished by a following procedure that has no effect when it is given alone. Brain-derived neurotrophic factor has a variety of roles in modulating both LTP and LTD. The Val66Met single nucleotide polymorphism is related to abnormal cortical plasticity. In this protocol, we propose a study to test the hypothesis that depotentiation is weaker in focal dystonia patients compared to healthy controls. In addition, motor cortical inhibition is decreased in focal dystonia. We will test the changes in motor cortical inhibition following different interventional procedures in focal dystonia. We will also test the relationship between depotentiation and LTP/LTD-like effects in focal dystonia patients.

Study population

We intend to study up to 20 patients with focal dystonia and 20 age-matched healthy volunteers. Subjects will complete up to 3 study visits involving 3 different interventional procedures. Various outcome measures will be performed during each study visit.

Design

This is a hypothesis-driven study. We will compare the depotentiation effect in patients with focal dystonia to that in healthy volunteers. Patients will be evaluated with a clinical rating scale during the screening visit. Three interventional procedures will be tested during three study visits. Specifically, PAS25-cTBS150 tests the primary hypothesis with a depotentiation effect. PAS25 tests LTP-like effect and PAS10 tests the LTD-like effect. We will investigate the difference in outcome measures between patients and healthy volunteers after the interventional procedures. We will perform genetic tests to identify the brain-derived neurotrophic factor genotype in the patients and healthy volunteers.

Outcome measures

The primary outcome measure is motor-evoked potential (MEP) induced by transcranial magnetic stimulation immediately after the interventional procedure of PAS25-cTBS150. We will compare MEP amplitude in patients with that in healthy volunteers to identify whether depotentiation is weaker in focal dystonia. The secondary outcome measures are MEP amplitudes at other time points after the PAS25-cTBS150 procedure. We will also perform exploratory studies to investigate the effects of interventional procedures of PAS25 and PAS10 alone. We will test the relationship between depotentiation and LTP/LTD-like effects in focal dystonia. We will also study other exploratory outcome measures such as: resting and active motor threshold, MEP recruitment curve, excitability of motor cortical circuits (short- and long-interval intracortical inhibition, and intracortical facilitation) after three different interventional procedures. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03206112
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Terminated
Phase
Start date September 20, 2017
Completion date April 9, 2020

See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1